# Perimenopause and GLP-1 medicines: clarify the weight and glucose questions

How changing body composition, glucose results and medication eligibility fit together during perimenopause.

Canonical: https://velri.co/blog/perimenopause-insulin-resistance-glp1-coordination-rachel
Publisher: Velri (https://velri.co/about)
Published: 2026-07-25
Updated: 2026-09-30
Editorial policy: https://velri.co/editorial-policy

Perimenopause can coincide with changes in body composition, but that does not make every weight change a sign of insulin resistance. A GLP-1 discussion is clearer when it separates the weight-management goal, glucose status and menopause symptoms. [1][2]

## What may be changing

In the longitudinal SWAN study, fat gain accelerated and lean mass declined during the menopause transition. The rate of total weight gain did not accelerate in the same way. This was an observational study of a group, not a forecast of one person’s weight trajectory. [1]

Those findings help explain why body changes can feel different even when the scale has not moved dramatically.

## What glucose testing can establish

Insulin resistance means the body’s cells respond less effectively to insulin. It often has no obvious symptoms. Prediabetes is assessed using tests such as A1c, fasting plasma glucose or an oral glucose tolerance test; tests that directly measure insulin resistance are mainly used in research. [2]

## Where medication selection fits

Weight-management medication eligibility considers body size and weight-related health conditions. The choice also depends on medical history, other medicines, potential adverse effects, preferences and cost. NIDDK emphasizes that response varies and that medication is used with nutrition and activity support. [3]

Menstrual and sleep symptoms still deserve their own assessment. Hormones fluctuate through perimenopause, and pregnancy can remain possible even with irregular periods. [4] Weight-management medicines should not be used during pregnancy or when planning pregnancy, making reproductive plans relevant to the discussion. [3]

A coherent plan identifies what each part addresses: symptoms of the transition, a measured glucose problem, or a weight-related health goal.

## Sources
[1] Changes in body composition and weight during the menopause transition. (2019). https://pubmed.ncbi.nlm.nih.gov/30843880/
[2] Insulin Resistance & Prediabetes - NIDDK (2025). https://www.niddk.nih.gov/health-information/diabetes/overview/what-is-diabetes/prediabetes-insulin-resistance
[3] Prescription Medications to Treat Overweight & Obesity - NIDDK (2025). https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity
[4] Perimenopause | The Menopause Society (2026). https://menopause.org/patient-education/menopause-topics/perimenopause

## About this information
General health information, not personal medical advice, diagnosis or treatment. A prescription is required and is never guaranteed.
Velri is a brand operated by Velri Management LLC, a Nevada limited liability company. Velri is a non-clinical technology and administrative services company. Velri does not provide medical advice, diagnosis, treatment, or pharmacy services, and does not direct the clinical judgment of any provider.
All medical consultations and prescriptions are provided directly by independent provider groups (Online Medical Care, P.C.; TMD of Kansas, P.A.; TMD of Texas, P.A.; and TMD of CA, PC), by a provider licensed in your state. Velri does not employ providers. A prescription is issued only if a provider determines it is clinically appropriate in their independent medical judgment.
All prescription products are dispensed by independent, licensed pharmacies. Velri does not own, operate, or control any pharmacy and does not dispense medication. You may opt out of using a given provider group or pharmacy at any time.
Compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state.
Velri is cash-pay. We do not bill Medicare, Medicaid, or commercial insurance. Refunds and order problems are addressed in the Terms of Use; your rights under applicable law are not limited. State availability and clinical eligibility apply.
Velri and telehealth are not for medical emergencies. If you are experiencing an emergency, call 911.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Care is available to eligible adults 18 and older in 47 states and D.C., United States only.
Notice of Privacy Practices: https://velri.co/privacy/notice-of-privacy-practices
Terms: https://velri.co/legal/terms
Provider group or pharmacy opt-out help: https://velri.co/contact and https://velri.co/standards#trust-support